Why the study?
Despite the frequent use of aspirin in childhood acute ischemic stroke prevention and management, major knowledge gaps remain regarding optimal pediatric use.
This review highlights the major knowledge gaps and the urgent need for high-quality clinical trials regarding optimal aspirin use and efficacy testing in childhood acute ischemic stroke.
Aspirin use in childhood AIS lacks trial guidance; leaves open optimal dosing, monitoring, and efficacy until RCTs are completed.
Aspirin is the most commonly prescribed antiplatelet agent worldwide, but evidence supporting its use varies by age and disease process. Despite its frequent use in childhood acute ischemic stroke prevention and management, major knowledge gaps exist about optimal pediatric aspirin use, particularly in this setting, where high-quality clinical trials are urgently needed. This review focuses upon the evidence for aspirin use in childhood acute ischemic stroke, includes a summary of aspirin pharmacology to highlight misconceptions and common clinical situations which may limit its efficacy, and discusses the techniques and potential role of laboratory monitoring of aspirin efficacy in children.
No takes yet. Share an insight, caveat, or question.
Boucher et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: